Antineuronal Autoantibodies in the Cerebrospinal Fluid and Serum From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control Subjects

• Published in: Biological psychiatry global open science Vol. 3; no. 4; pp. 1116 - 1121
• Main Authors: Sørensen, Nina Vindegaard, Nilsson, Anna Christine, Orlovska-Waast, Sonja, Jeppesen, Rose, Christensen, Rune Haubo Bojesen, Benros, Michael Eriksen
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.2023; Elsevier
• Subjects: Autoantibodies; Autoimmune encephalitis; Biomarkers; Cerebrospinal fluid; Depression; Immunology; Techniques and Methods; Biomarkers; Depression; Autoantibodies; Immunology; Cerebrospinal fluid; Autoimmune encephalitis
• ISSN: 2667-1743; 2667-1743
• DOI: 10.1016/j.bpsgos.2022.10.007

No large studies have investigated the prevalence of cerebrospinal fluid antineuronal autoantibodies in isolated depression. In this case-control study comparing 106 patients with isolated depression (ICD-10 code F32) with 106 healthy control subjects, cerebrospinal fluid and serum samples were tested for 7 immunoglobulin G autoantibodies using commercial fixed cell-based assays. To explore validity of methods, positive samples were retested twice by cell-based assays and once by tissue-based assays (monkey cerebellum). The prevalence of any of the antineuronal autoantibodies in cerebrospinal fluid was 0.0% in both groups and the seroprevalence was 0.9% in both groups, based on consistent findings in cell-based assays. However, all samples were negative by the tissue-based assay. Evaluation of antineuronal autoantibodies in cerebrospinal fluid cannot be recommended routinely for patients with isolated depression of moderate severity. Future studies of isolated depression should consider much larger sample sizes and evaluation of antineuronal autoantibodies using modalities other than commercial kits.